Genetic variation in 11β-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with polycystic ovary syndrome

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 6, 2006, Pages 2295-2302

  Gambineri, Alessandra ^a   Vicennati, Valentina ^a   Genghini, Silvia ^a   Tomassoni, Federica ^a   Pagotto, Uberto ^a   Pasquali, Renato ^a   Walker, Brian R ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; DEXAMETHASONE; HYDROCORTISONE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRASTERONE SULFATE; TETRACOSACTIDE; CORTICOTROPIN;

ADRENAL DISEASE; ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERANDROGENISM; INTRON; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; OBESITY; OVARY POLYCYSTIC DISEASE; PREDICTION; PRIORITY JOURNAL; BLOOD; CASE CONTROL STUDY; GENETICS;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ADRENOCORTICOTROPIC HORMONE; ADULT; CASE-CONTROL STUDIES; CHOLESTEROL, LDL; DEHYDROEPIANDROSTERONE SULFATE; FEMALE; GENOTYPE; HUMANS; HYPERANDROGENISM; POLYCYSTIC OVARY SYNDROME; VARIATION (GENETICS);

EID: 33744954783     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-2222     Document Type: Article

References (34)

1. Seckl JR, Walker BR 2001 11β-Hydroxysteroid dehydrogenase type 1: a tissue-specific amplifier of glucocorticoid action. Endocrinology 142:1371-1376
2. Tomlinson JW, Walker EA, Bujalska IJ, Draper N, Lavery GG, Cooper MS, Hewison M, Stewart PM 2004 11β-Hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 25:831-866
3. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS 2001 A transgenic model of visceral obesity and the metabolic syndrome. Science 294:2166-2170
4. Morton NM, Holmes MC, Fiévet C, Staels B, Tailleux A, Mullins JJ, Seckl JR 2001 Improved lipid and lipoprotein profile, hepatic insulin sensitivity and glucose tolerance in 11β-hydroxysteroid dehydrogenase 1 null mice. J Biol Chem 276:41293-41300
5. Morton NM, Paterson JM, Masuzaki H, Holmes MC, Staels B, Fievet C, Walker BR, Flier JS, Mullins JJ, Seckl JR 2004 Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11β-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 53:931-938
6. Rask E, Walker BR, Soderberg S, Livingstone DE, Eliasson M, Johnson O, Andrew R, Olsson T 2002 Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11β-hydroxysteroid dehydrogenase type 1 activity. J Clin Endocrinol Metab 87:3330-3336
7. Walker BR, Connacher AA, Lindsay RM, Webb DJ, Edwards CRW 1995 Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. J Clin Endocrinol Metab 80:3155-3159
8. Andrews RC, Rooyackers O, Walker BR 2003 Effects of the 11β-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab 88:285-291
9. Sandeep TC, Andrew R, Homer NZ, Andrews RC, Smith K, Walker BR 2005 Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone. Diabetes 54:872-879
10. Nair S, Lee YH, Lindsay RS, Walker BR, Tatarani PA, Bogardus C, Baier LJ, Permana PA 2004 11β-Hydroxysteroid dehydrogenase type 1: genetic polymorphisms are associated with type 2 diabetes in Pima Indians independently of obesity and expression in adipocyte and muscle. Diabetologia 47:1088-1095
11. Franks PW, Knowler WC, Nair S, Koska J, Lee YH, Lindsay RS, Walker BR, Looker HC, Permana PA, Tatarani PA, Hanson RL 2004 Interaction between an 11βHSD1 gene variant and birth era modifies risk of hypertension in Pima Indians. Hypertension 44:681-688
12. Draper N, Walker EA, Bujalska IJ, Tomlinson JW, Chalder SM, Arlt W, Lavery GG, Bedendo O, Ray DW, Laing I, Malunowicz E, White PC, Hewison M, Mason PJ, Connell JM, Shackleton CHL, Stewart PM 2003 Mutations in the gene encoding 11β-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency. Nat Genet 34:434-439
13. Phillipov G, Palermo M, Shackleton CH 1996 Apparent cortisone reductase deficiency: a unique form of hypercortisolism. J Clin Endocrinol Metab 81:3855-3860
14. Rodin A, Thakkar H, Taylor NJ, Clayton R 1994 Hyperandrogenism in polycystic ovary syndrome: evidence of dysregulation of 11β-hydroxysteroid dehydrogenase. N Engl J Med 330:460-465
15. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE 2005 Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 90:1929-1935
16. Legro RS, Kunselman AR, Dodson WC, Dunaif A 1999 Prevalence and predictions of the risk of type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84:165-169
17. Gambineri A, Pelusi C, Manicardi E, Vicennati V, Cacciari M, Morselli-Labate AM, Pagotto U, Pasquali R 2004 Glucose intolerance in a large cohort of Mediterranean women with polycystic ovary syndrome. Diabetes 53:2353-2358
18. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R 1998 Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 338:1876-1880
19. Ferriman D, Gallwey JD 1961 Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 21:1440-1447
20. Gambineri A, Pelusi C, Genghini S, Morselli-Labate AM, Cacciari M, Pagotto U, Pasquali R 2004 Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 60:241-249
21. The Rotterdam ESHRE/ASMR-Sponsored PCOS Consensus Workshop Group 2004 Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Human Reprod 19:41-47
22. Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, Fiorini S, Cognini GE, Filicori M, Morselli-Labate AM 2000 Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 85:2767-2774
23. World Health Organization 1997 Preventing and managing the global epidemic of obesity: report of the World Health Organization consultation on obesity. Geneva: World Health Organization
24. Pasquali R, Gambineri A, Anconetani B, Vicennati V, Colitta D, Caramelli E, Casimirri F, Morselli-Labate AM 1999 The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment. Clin Endocrinol (Oxf) 50:517-527
25. Vicennati V, Pasquali R 2000 Abnormalities of the hypothalamic-pituitary- adrenal axis in nondepressed women with abdominal obesity and relations with insulin resistance: evidence for a central and peripheral alteration. J Clin Endocrinol Metab 85:4093-4098
26. Friedewald WT, Levy RI, Fredrickson DS 1972 Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502
27. Mather KJ, Hunt AE, Steinberg HO, Paradisi G, Hook G, Kats A, Quon MJ, Baron AD 2001 Repeatability characteristic of simple indices of insulin resistance: implications for research applications. J Clin Endocrinol Metab 86:5457-5464
28. Matsuda M, De Fronzo RA 1999 Insulin sensitivity indices obtained from oral glucose tolerance testing. Diabetes Care 22:1462-1470
29. Morán C, Knochenhauer ES, Boots LR, Azziz R 1999 Adrenal androgen excess in hyperandrogenism: relation to age and body mass. Fertil Steril 71:671-674
30. San Millán JL, Botella-Carretero JI, Alvarez-Blasco F, Luque-Ramírez M, Sancho J, Moghetti P, Escobar-Morreale HF 2005 A study of the hexose-6-phosphate dehydrogenase gene R453Q and 11β-hydroxysteroid dehydrogenase type 1 gene 83557insA polymorphisms in the polycystic ovary syndrome. J Clin Endocrinol Metab 90:4157-4162
31. White PC 2005 Genotypes at 11β-hydroxysteroid dehydrogenase type 11B1 and hexose-6-phosphate dehydrogenase loci are not risk factors for apparent cortisone reductase deficiency in a large population-based sample. J Clin Endocrinol Metab 90:5880-5883
32. Zawadzki JK, Dunaif A 1992 Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, eds. Polycystic ovary syndrome. Boston: Blackwell Scientific; 377-384
33. Hines GA, Smith ER, Azziz R 2001 Influence of insulin and testosterone on adrenocortical steroidogenesis in vitro: preliminary studies. Fertil Steril 76:730-735
34. Andrew R, Phillips DIW, Walker BR 1998 Obesity and gender influence cortisol secretion and metabolism in man. J Clin Endocrinol Metab 83:1806-1809